![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Eli Lilly
Main (gene editing) focus: Genetic disorders in the liver and nervous system
Company stage: Commercial
Diseases (gene editing): Liver diseases and diseases of the central nervous system
Genome editing tool: ADAR RNA editing, Arcus Meganuclease
Funding stage: Public (NASDAQ:LLY)
Location: Indianapolis, Indiana, USA
Website: https://www.lilly.com/
Pipeline: https://www.lilly.com/discovery/clinical-development-pipeline
Gene editing partnerships: ProQR Therapeutics, Precision Biosciences
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_lilly_logo_c3bcd8947e_6ce7f2371d.jpg)
Eli Lilly is a big pharma company with several commercialised medicines in its portfolio. The company's involvment in the genome-editing space comes primarily through its collaboration with Precision Biosciences, where Eli Lilly gets access to the ARCUS meganuclease gene-editing technology to treat genetic diseases of muscle, CNS and liver. Another collaboration in this space is with ProQR Therapeutics, where Eli Lilly gains access to an ADAR-based RNA-editing technology.